Assignee
SANOFI AVENTIS US LLC
US·6 granted patents·13 pending applications·4 citations·filing 2005–2025
Top patents by PatentIndex Score
19 records- 0187US2025216392A1Novel anti-cd38 antibodies for the treatment of cancerSANOFI AVENTIS US LLC·Filed 2024·Application pending·0 cites
- 0271US2026042861A1Formulations of anti-cd38 antibodies for subcutaneous administrationSANOFI AVENTIS US LLC·Filed 2025·Application pending·0 cites
- 0370US7713548B2Amorphous solid dispersionsSANOFI AVENTIS US LLC·Filed 2008·Granted May 11, 2010·1 cites·33 claims
- 0466US11939390B2Methods of treating multiple myelomaSANOFI AVENTIS US LLC·Filed 2020·Granted Mar 26, 2024·1 cites·19 claims
- 0561US12533411B2Compositions comprising anti-CD38 antibodies and carfilzomibSANOFI AVENTIS US LLC·Filed 2021·Granted Jan 27, 2026·0 cites·10 claims
- 0659US2024190984A1Methods of treating multiple myelomaSANOFI AVENTIS US LLC·Filed 2024·Application pending·0 cites
- 0756US7683062B2Crystalline formSANOFI AVENTIS US LLC·Filed 2008·Granted Mar 23, 2010·0 cites·11 claims
- 0855US7332593B2Variants of TRAF2 which act as an inhibitor of TNF-alpha (TNFα) signaling pathwaySANOFI AVENTIS US LLC·Filed 2005·Granted Feb 19, 2008·0 cites·4 claims
- 0955US2021188996A1Formulations of anti-cd38 antibodies for subcutaneous administrationSANOFI AVENTIS US LLC·Filed 2020·Application pending·0 cites
- 1052US9090411B2Apparatus and method for loading and unloading containersSANOFI AVENTIS US LLC·Filed 2014·Granted Jul 28, 2015·2 cites·10 claims
- 1152US2025177519A1Use of isatuximab in combination with other agents for the treatment of multiple myelomaSANOFI AVENTIS US LLC·Filed 2023·Application pending·0 cites
- 1251US2021171653A1Use of isatuximab for the treatment of relapsed and/or refractory multiple myelomaSANOFI AVENTIS US LLC·Filed 2020·Application pending·0 cites
- 1350US2014323577A1Methods for reducing the risk of conversion to clinically definite multiple sclerosisSANOFI AVENTIS US LLC·Filed 2014·Application pending·0 cites
- 1448US2007197597A1Process for the preparation of tryptase inhibitorsSANOFI AVENTIS US LLC·Filed 2006·Application pending·0 cites
- 1547US2010174088A1Process for the preparation of benzimidazol thienylamine compounds and derivatives thereof useful as sodium/proton exchanger type 3 inhibitorsSANOFI AVENTIS US LLC·Filed 2009·Application pending·0 cites
- 1646US2008038359A1Stable Nanoparticle FormulationsSANOFI AVENTIS US LLC·Filed 2007·Application pending·0 cites
- 1738US2013156735A1Use of the combination of teriflunomide and interferon beta for treating multiple sclerosisSANOFI AVENTIS US LLC·Filed 2013·Application pending·0 cites
- 1838US2022135696A1Use of isatuximab for the treatment of multiple myelomaSANOFI AVENTIS US LLC·Filed 2021·Application pending·0 cites
- 1935US2011224214A1Process for preparing polymorphSANOFI AVENTIS US LLC·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SANOFI AVENTIS US LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →